Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celltrion Partners With Intract Pharma For Oral Infliximab

Celltrion Partners With Intract Pharma For Oral Infliximab

Executive Summary

South Korea’s Celltrion has partnered with oral drug delivery specialist Intract Pharma for the formulation of oral infliximab for the treatment of inflammatory bowel disease. Celltrion has also reported year-on-year and quarter-on-quarter growth in sales, along with plans to grow in the US market.

You may also be interested in...



Celltrion To Begin Denosumab Trials Within Days

Celltrion has announced plans to proceed to Phase I clinical trials of its Prolia/Xgeva (denosumab) biosimilar candidate. The company is also working on biosimilar versions of bevacizumab, omalizumab and ustekinumab for both Europe and the US.

Celltrion Extends Remsima SC Indications

Celltrion has received a positive opinion from the CHMP for five additional indications for its Remsima SC biosimilar, expanding the scope of the subcutaneous infliximab product that was launched earlier this year.

FDA Reveals Details Of Shilpa’s Violations

The FDA has revealed details of its recent warning letter to Shilpa, which cites the company’s failure to adequately investigate out-of-specification results and complaints as well as to follow written procedures for complaint handling.

Topics

Related Companies

UsernamePublicRestriction

Register

MT142578

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel